News

AQX-1125 is a small molecule activator of SHIP1 suitable for oral, once daily dosing and it has been evaluated in multiple preclinical studies and clinical trials. The randomized,

The joint collaboration will focus on biomarkers that may facilitate therapeutic approaches targeting alpha-synuclein, a protein potentially involved in the onset and progression of PD. MJFF CEO Todd

Sovaldi is indicated to treat chronic hepatitis C infection as a component of a combination antiviral treatment regimen. In February 2015, Gilead appointed Mylan as its exclusive distributor

BL-8040 is a clinical-stage drug candidate designed to treat AML, as well as other hematological indications. The company intends to report top-line results from the trial in the

Around 120 patients at ten sites in the US will be included in the randomized, double-blind, placebo-controlled trial, which will evaluate the safety, tolerability and efficacy of KD026

The company is investing DKK1.5bn ($223m) in this new facility, which is designed to produce active pharmaceutical ingredients for NovoSeven and future products to treat haemophilia. With the

The article details tarextumab’s anti-tumor effects alone and in combination with chemotherapy and elucidates the drug candidate’s mechanisms of activity. Additionally, data is presented describing the basis for

If successful, guanabenz (formerly called MRF-008) could be the first MS treatment to focus on protecting myelin from damage, which is the hallmark of MS, rather than on

The orphan designation is held by the company’s European agent, Biological Consulting Europe, which is located in the UK. Advanced Inhalation Therapies chief medical officer Dr David Greenberg